Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.
Matteo MolicaSalvatore PerroneCostanza AndriolaMarco RossiPublished in: Cancers (2023)
In the last few years, molecularly targeted agents and immune-based treatments (ITs) have significantly changed the landscape of anti-cancer therapy. Indeed, ITs have been proven to be very effective when used against metastatic solid tumors, for which outcomes are extremely poor when using standard approaches. Such a scenario has only been partially reproduced in hematologic malignancies. In the context of acute myeloid leukemia (AML), as innovative drugs are eagerly awaited in the relapsed/refractory setting, different ITs have been explored, but the results are still unsatisfactory. In this work, we will discuss the most important clinical studies to date that adopt ITs in AML, providing the basis to understand how this approach, although still in its infancy, may represent a promising therapeutic tool for the future treatment of AML patients.
Keyphrases
- acute myeloid leukemia
- cancer therapy
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- ejection fraction
- squamous cell carcinoma
- small cell lung cancer
- newly diagnosed
- drug delivery
- chronic kidney disease
- peritoneal dialysis
- type diabetes
- acute lymphoblastic leukemia
- patient reported outcomes
- weight gain
- current status
- physical activity
- insulin resistance
- patient reported
- glycemic control
- hodgkin lymphoma